USD 30.98
(-0.03%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 60.01 Million USD | 120.38% |
2022 | 27.23 Million USD | 71.57% |
2021 | 15.87 Million USD | 706.73% |
2020 | -2.61 Million USD | -160.07% |
2019 | 4.35 Million USD | -43.79% |
2018 | 7.74 Million USD | -41.7% |
2017 | 13.28 Million USD | 1793.02% |
2016 | 702 Thousand USD | -80.34% |
2015 | 3.57 Million USD | 143.25% |
2014 | -8.25 Million USD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | 24.83 Million USD | 1173.66% |
2024 Q2 | 28.97 Million USD | 16.65% |
2023 Q3 | 9.35 Million USD | -50.03% |
2023 Q4 | 1.95 Million USD | -79.16% |
2023 FY | 60.01 Million USD | 120.38% |
2023 Q2 | 18.72 Million USD | -1.14% |
2023 Q1 | 18.93 Million USD | 360.49% |
2022 Q3 | 4.61 Million USD | -59.45% |
2022 FY | 27.23 Million USD | 71.57% |
2022 Q1 | 9.39 Million USD | 306.07% |
2022 Q4 | -7.26 Million USD | -257.54% |
2022 Q2 | 11.37 Million USD | 21.07% |
2021 Q1 | 7.12 Million USD | 276.02% |
2021 Q2 | 16.48 Million USD | 131.32% |
2021 Q3 | -3.18 Million USD | -119.29% |
2021 Q4 | -4.56 Million USD | -43.43% |
2021 FY | 15.87 Million USD | 706.73% |
2020 Q3 | -3.29 Million USD | -189.22% |
2020 Q2 | 3.69 Million USD | 695.69% |
2020 Q1 | 464 Thousand USD | 103.67% |
2020 FY | -2.61 Million USD | -160.07% |
2020 Q4 | -4.04 Million USD | -22.92% |
2019 Q4 | -12.63 Million USD | -189.53% |
2019 FY | 4.35 Million USD | -43.79% |
2019 Q3 | -4.36 Million USD | -148.54% |
2019 Q2 | 8.99 Million USD | 84.54% |
2019 Q1 | 4.87 Million USD | 200.39% |
2018 FY | 7.74 Million USD | -41.7% |
2018 Q1 | -3.08 Million USD | -7445.24% |
2018 Q2 | 9.37 Million USD | 403.89% |
2018 Q3 | 6.56 Million USD | -30.02% |
2018 Q4 | -4.85 Million USD | -173.97% |
2017 Q4 | 42 Thousand USD | -97.64% |
2017 Q1 | 4.79 Million USD | 4033.62% |
2017 FY | 13.28 Million USD | 1793.02% |
2017 Q2 | 6.67 Million USD | 39.19% |
2017 Q3 | 1.77 Million USD | -73.36% |
2016 Q1 | 1.7 Million USD | 0.0% |
2016 Q4 | 116 Thousand USD | 106.51% |
2016 Q3 | -1.78 Million USD | -370.41% |
2016 Q2 | 659 Thousand USD | -61.44% |
2016 FY | 702 Thousand USD | -80.34% |
2015 Q1 | 5.97 Million USD | 0.0% |
2015 FY | 3.57 Million USD | 143.25% |
2014 FY | -8.25 Million USD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Esperion Therapeutics, Inc. | -155.56 Million USD | 138.579% |
Theratechnologies Inc. | -10.62 Million USD | 664.741% |
Safety Shot Inc | -12.18 Million USD | 592.566% |
Cosmos Health Inc. | -21.83 Million USD | 374.905% |
Cronos Group Inc. | -81.37 Million USD | 173.751% |
Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 71.29% |
Kala Pharmaceuticals, Inc. | -39.15 Million USD | 253.283% |
Organogenesis Holdings Inc. | 12.52 Million USD | -379.162% |
Universe Pharmaceuticals INC | -3.52 Million USD | 1801.697% |
ProPhase Labs, Inc. | -21.61 Million USD | 377.68% |
Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 1376.643% |
Dynavax Technologies Corporation | -37.02 Million USD | 262.08% |
Radius Health, Inc. | -3.92 Million USD | 1629.045% |
China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 2486.076% |
Alvotech | -354.86 Million USD | 116.912% |
Sunshine Biopharma, Inc. | -4.78 Million USD | 1354.154% |
Alpha Teknova, Inc. | -35.56 Million USD | 268.757% |
Intra-Cellular Therapies, Inc. | -159.38 Million USD | 137.655% |
SCYNEXIS, Inc. | 72.66 Million USD | 17.413% |
Harrow Health, Inc. | 580 Thousand USD | -10247.414% |
Biofrontera Inc. | -22.67 Million USD | 364.651% |
DURECT Corporation | -36.88 Million USD | 262.713% |
Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 1239.021% |
ANI Pharmaceuticals, Inc. | 46.97 Million USD | -27.77% |
OptiNose, Inc. | -22.74 Million USD | 363.825% |
RedHill Biopharma Ltd. | 12.63 Million USD | -375.103% |
Aquestive Therapeutics, Inc. | -15.1 Million USD | 497.398% |
Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 1066.298% |
SIGA Technologies, Inc. | 83.62 Million USD | 28.23% |
Lifecore Biomedical, Inc. | 9.33 Million USD | -543.179% |
Shineco, Inc. | -17.06 Million USD | 451.667% |
Phibro Animal Health Corporation | 53.31 Million USD | -12.567% |
Procaps Group S.A. | 52.32 Million USD | -14.699% |
TherapeuticsMD, Inc. | -8.52 Million USD | 804.153% |
Regencell Bioscience Holdings Limited | -4.73 Million USD | 1367.014% |
Viatris Inc. | 766.2 Million USD | 92.167% |
Sunshine Biopharma, Inc. | -4.78 Million USD | 1354.154% |
Rockwell Medical, Inc. | -6.67 Million USD | 999.775% |
Incannex Healthcare Limited | -30.04 Million USD | 299.777% |
Aytu BioPharma, Inc. | -5.25 Million USD | 1242.273% |
Tilray Brands, Inc. | -174.74 Million USD | 134.344% |
Collegium Pharmaceutical, Inc. | 166.96 Million USD | 64.054% |
Silver Spike Investment Corp. | 7.34 Million USD | -717.631% |
Neurocrine Biosciences, Inc. | 250.9 Million USD | 76.08% |
Journey Medical Corporation | -2.07 Million USD | 2995.08% |
Alimera Sciences, Inc. | -1.47 Million USD | 4179.878% |
Petros Pharmaceuticals, Inc. | -13.61 Million USD | 540.724% |
Assertio Holdings, Inc. | -243.53 Million USD | 124.643% |
Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 1118.519% |
Embecta Corp. | 221.5 Million USD | 72.905% |
Cyclo Therapeutics, Inc. | -20.05 Million USD | 399.326% |
Procaps Group, S.A. | 38.97 Million USD | -53.991% |
PainReform Ltd. | -9.58 Million USD | 726.2% |
Avadel Pharmaceuticals plc | -137.84 Million USD | 143.537% |
Hempacco Co., Inc. | -8.81 Million USD | 781.038% |
Talphera, Inc. | -16.88 Million USD | 455.35% |
Pacira BioSciences, Inc. | 87.67 Million USD | 31.548% |
Alvotech | -354.86 Million USD | 116.912% |
Lantheus Holdings, Inc. | 364.64 Million USD | 83.541% |
Kamada Ltd. | 10.06 Million USD | -496.333% |
Indivior PLC | -4 Million USD | 1600.375% |
Currenc Group, Inc. | -6.64 Million USD | 1003.054% |
Evoke Pharma, Inc. | -7.43 Million USD | 907.642% |
Flora Growth Corp. | -50.35 Million USD | 219.186% |
Cyclo Therapeutics, Inc. | -20.05 Million USD | 399.326% |
Evolus, Inc. | -49.23 Million USD | 221.9% |
HUTCHMED (China) Limited | 18.37 Million USD | -226.612% |
Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 69.534% |
Akanda Corp. | -10.05 Million USD | 697.083% |